sanjay rathod’s Post

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gPMYh7E4 #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gvHfMfqy #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dJ9P9Jx2 #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/eywK5RQV #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gEv_9bDb #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gYh2wUfN #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gNA2-r3s #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dUeM-F5p #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/e3zzXwip #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/d8dhJbPs #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships